Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 226 to 240 of 309 results for breast cancer

  1. Patient decision aids

    condition Cancer Lynch syndrome: should I take aspirin to reduce my chance of getting bowel cancer? Medicines to reduce the...

  2. Alcohol-use disorders: diagnosis, assessment and management of harmful drinking (high-risk drinking) and alcohol dependence (CG115)

    This guideline covers identifying, assessing and managing alcohol-use disorders (harmful drinking and alcohol dependence) in adults and young people aged 10 to 17 years. It aims to reduce harms (such as liver disease, heart problems, depression and anxiety) from alcohol by improving assessment and setting goals for reducing alcohol consumption.

  3. Abortion care. Patient decision aid on choosing between medical or surgical abortion before 14 weeks

    by day. Having an abortion does not increase the risk of infertility, breast cancer or mental health issues. You can usually choose...

  4. Suspected neurological conditions: recognition and referral (NG127)

    This guideline covers the initial assessment of symptoms and signs that might indicate a neurological condition. It helps non-specialist healthcare professionals to identify people who should be offered referral for specialist investigation.

  5. Physical health of people in prison (NG57)

    This guideline covers assessing, diagnosing and managing physical health problems of people in prison. It aims to improve health and wellbeing in the prison population by promoting more coordinated care and more effective approaches to prescribing, dispensing and supervising medicines.

  6. Prioritisation board decisions 2024

    Our centralised approach to prioritising guidance topics ensures that we produce guidance that is relevant, timely, accessible, and has demonstrable impact.

  7. Robot-assisted surgery for soft tissue procedures: early value assessment (HTE21)

    Early value assessment (EVA) guidance on robot-assisted surgery for soft tissue procedures....

  8. Familial breast cancer (CG41)

    This guidance has been updated and replaced by NICE guideline CG164.

  9. Familial breast cancer (CG14)

    This guidance has been updated and replaced by NICE guideline CG41.

  10. Abortion care (NG140)

    This guideline covers care for women of any age (including girls and young women under 18) who request an abortion. It aims to improve the organisation of services and make them easier for women to access. Detailed recommendations on conducting abortions at different gestational stages are also included, to ensure that women get the safest and most effective care possible.

  11. Taxanes for the treatment of breast cancer (TA6)

    This guidance has been replaced by NICE technology appraisal guidance 30 [Replaced by NICE guideline CG81].

  12. Taxanes for the treatment of breast cancer (TA30)

    This guidance has been replaced by NICE guideline CG81.

  13. Cardiovascular disease prevention (PH25)

    This guideline covers the main risk factors linked with cardiovascular disease: poor diet, physical inactivity, smoking and excessive alcohol consumption. It aims to reduce the high incidence of cardiovascular disease. This, in turn, will help prevent other major causes of death and illness, such as type 2 diabetes and many cancers.

  14. Vitamin D: supplement use in specific population groups (PH56)

    This guideline covers vitamin D supplement use. It aims to prevent vitamin D deficiency among specific population groups including infants and children aged under 4, pregnant and breastfeeding women, particularly teenagers and young women, people over 65, people who have low or no exposure to the sun and people with dark skin.

  15. Linzagolix for treating moderate to severe symptoms of uterine fibroids (TA996)

    Evidence-based recommendations on linzagolix (Yselty) for treating moderate to severe symptoms of fibroids in adults of reproductive age.